CASE REPORT

Open Access

Dual checkpoint inhibitor-associated eosinophilic enteritis

J. Yang¹, S. M. Lagana², Y. M. Saenger^{1,3} and R. D. Carvajal^{1,3*}

Abstract

Background: Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events.

Case presentation: We report a case of dual checkpoint inhibitor-associated hypereosinophilia and eosinophilic enteritis in a patient with advanced cutaneous melanoma. Rapid resolution of peripheral eosinophilia and associated symptoms was achieved with steroids alone.

Conclusions: Immune checkpoint inhibition can trigger inflammation in virtually any organ in the body, leading to diverse clinical manifestations. To our knowledge, this is the first case report of eosinophilic enteritis due to ipilimumab plus nivolumab.

Keywords: Melanoma, Checkpoint inhibition, Eosinophilia, Eosinophilic enteritis

Introduction

Immune checkpoint inhibition with anti-PD-1 (programmed death 1) and anti-CLTA-4 (cytotoxic T-lymphocyte associated protein 4) agents has revolutionized the treatment of various cancers, but can be associated with a diverse range of immune-related adverse events including pneumonitis, colitis, and rare cases of myocarditis. Eosinophilic enteritis is a rare primary eosinophilic gastrointestinal disorder, first described in 1937, characterized by gastrointestinal symptoms in the presence of pathological eosinophilic infiltration of the intestinal wall without secondary causes of gut eosinophilia. To our knowledge, this is the first reported case of eosinophilic enteritis associated with ipilimumab plus nivolumab.

Case presentation

A 68-year old Caucasian man was referred to our medical oncology clinic in August 2017 for management of a stage IIIB (AJCC version 7) cutaneous melanoma. He was diagnosed with a 2 mm thick melanoma over the right scalp in December 2012 that was excised. Sentinel lymph node

biopsy was negative. He remained disease-free until August 2017 when he noticed a pruritic scalp nodule located approximately 2 cm from the prior skin graft that was biopsy-proven to be an in-transit recurrence of the melanoma. He underwent repeat excision, with pathological staging demonstrating a stage IIIB (pT4apN2cM0) melanoma. Molecular testing was notable for a *GNA11* Q209L mutation that was also found in the previous specimen from 2012. MRI brain and CT chest, abdomen, and pelvis were negative for distant metastases. He was started on adjuvant pembrolizumab on 12/14/2017. Shortly after the first dose, he developed an enlarging right supraclavicular lymph node. Fine needle aspiration of the lymph node revealed metastatic melanoma. Repeat scans after 3 additional doses of pembrolizumab demonstrated new hepatic lesions. Treatment was intensified with the addition of talimogene laherparepvec (T-VEC) injections into the supraclavicular lymph node. He developed a maculopapular rash that was managed with topical hydrocortisone. There was significant decrease in the size of the injected lymph node with initially stable visceral disease, but MRI abdomen on 6/8/2018 after 5 concurrent doses of T-VEC and pembrolizumab showed interval growth in several hepatic lesions.

He was transitioned to dual checkpoint inhibition with ipilimumab 3 mg/kg plus nivolumab 1 mg/kg and received his first dose on 6/21/2018. Blood work on 7/9/2018 was notable for an absolute eosinophil count

* Correspondence: rdc2150@cumc.columbia.edu

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

³Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA

Full list of author information is available at the end of the article

© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

(AEC) of $700/\text{mm}^3$ [normal range 30–350; peripheral eosinophilia defined as $\text{AEC} \geq 500/\text{mm}^3$] (Fig. 1). He received 2 additional doses of ipilimumab plus nivolumab on 7/12/2018 and 8/1/2018 with concurrent stereotactic body radiation therapy (SBRT) to 2 liver lesions (50 Gy over 5 fractions to each lesion). He returned for his final dose of combination therapy on 8/23/18, but treatment was held for worsening pruritus, rash, non-productive cough, and new transaminitis (AST 60, ALT 151). Around this time, he also developed vague gastrointestinal symptoms consisting of abdominal pain, bloating, nausea, and diarrhea. His AEC continued to rise, peaking at $3600/\text{mm}^3$ on 8/21/2018. He did not have rectal bleeding or ascites. Stool and serologic studies were negative for parasitic infection. Restaging scans on 8/27/2018 showed further disease progression in the liver and the development of a new soft tissue paraspinal lesion. He was evaluated by a gastroenterologist and underwent an upper endoscopy which revealed no gross abnormalities, but biopsy of the duodenum revealed a prominent eosinophilic infiltrate (80–100 eosinophils per HPF) consistent with eosinophilic enteritis (Fig. 2).

He was started on prednisone 1 mg/kg daily with rapid improvement in his peripheral eosinophilia, rash, cough, and gastrointestinal symptoms. When the prednisone was tapered off, he developed recurrent symptoms with a concomitant rise in his AEC. He was restarted on prednisone 15 mg daily with normalization of his AEC. Subsequent scans demonstrated essentially stable disease for three months, although minor growth was noted in several cutaneous lesions. He received additional lines of

therapy including off-label trametinib for *GNA11*-mutant melanoma, nivolumab monotherapy, and combination chemotherapy with carboplatin, vinblastine, and dacarbazine. The most recent AEC was normal off prednisone. Most recent imaging showed disease progression in the lung, and he was restarted on ipilimumab plus nivolumab in combination with T-VEC injections.

Discussion

Primary eosinophilic gastrointestinal disorders encompass a group of rare diseases characterized by pathologic eosinophilic infiltration of the gastrointestinal tract in the absence of other identifiable causes of gut eosinophilia. Eosinophilic gastritis, enteritis, and gastroenteritis are generally grouped together due to clinical similarities, but it is unclear whether these represent distinct entities or share a common pathological process [1]. Abdominal pain, nausea, and vomiting are common presenting symptoms, and the majority of patients have peripheral eosinophilia. There are no consensus histopathologic criteria for diagnosis, but experts have proposed guidelines suggesting that greater than 25 eosinophils per high power field (HPF), in conjunction with eosinophilic acute cryptitis, is abnormal [2]. The diagnosis of eosinophilic enteritis additionally requires the exclusion of secondary causes of intestinal eosinophilia such as parasitic infections, inflammatory bowel disease, autoimmune vasculitides, and culprit drugs e.g., gold therapy, oral hypoglycemic agents, and non-steroidal anti-inflammatory drugs (NSAIDs) [3].

Fig. 1 Absolute eosinophil count over treatment course. First black arrow – initiation of prednisone 1 mg/kg. Red arrow – steroid dose tapered down to prednisone 5 mg daily. Second black arrow – steroid dose increased to prednisone 15 mg daily. Asterisk – unknown eosinophil count

Fig. 2 Duodenal biopsy showed extensive eosinophilic infiltrate. A – Greater than 100 eosinophils per high-power field, predominantly in lamina propria (hematoxylin and eosin, 40X view). B – Eosinophilic infiltration within duodenal crypts as indicated by black arrows (60X view)

The molecular pathogenesis of eosinophilic gastroenteritis is thought to be mediated by a type 2 helper T cell (Th2)-driven immune response that triggers eosinophil chemotaxis and activation. Transcriptomic analysis of gastric biopsies obtained from patients with eosinophilic gastroenteritis reveals activation of the Th2 cytokine signaling pathways IL-4, IL-5, and IL-13. Upregulation of the chemokine CCL26 (eotaxin-3), a known eosinophil chemoattractant and downstream target of IL-4 and IL-13, further corroborates the central role of Th2-driven immunity [4–7]. Similar to our patient who has a history of multiple allergies to dust, pollen, latex, and several medications (penicillin, pregabalin, ibuprofen), affected individuals tend to have atopic phenotypes consisting of asthma, eczema, and allergies to food or medicine. In the case we present, checkpoint inhibition may have provoked a similar immune response in the duodenum leading to eosinophilic inflammation. Indeed, T cell co-stimulation through CD28 and B7–2 plays an important role in the Th2-mediated immune response that promotes bronchial asthma. Administration of a CTLA-4 immunoglobulin (fusion protein consisting of extracellular domain of CTLA-4 and a human γ -1 constant region) blocks this interaction and reduces eosinophil accumulation and Th2 cytokine production [8]. Thus, we may surmise that checkpoint inhibition with ipilimumab could trigger allergic conditions such as eosinophilic enteritis. Alternatively, the accumulation of gut eosinophils may have been secondary to a hypereosinophilic syndrome-like condition induced by immunotherapy.

Peripheral eosinophilia, long observed during the course of IL-2 therapy due to induction of IL-4 and IL-5 [9–11], was recently documented as a new, rare biological effect of checkpoint inhibition. A retrospective case series based on a French pharmacovigilance registry included 909 patients who received anti-PD-1 or anti-PD-L1 therapy between 2013 and 2016 [12]. A total of 26 patients (2.8%) were deemed to have immune-related eosinophilia, the majority of whom were treated for

advanced melanoma. The median time to increase in eosinophil count was 3.0 months after the first cycle of therapy, with peak eosinophilia (median peak $1000/\text{mm}^3$) occurring after a median of 6.4 months. Notably, no patient developed any clinical manifestations related to eosinophilia. Our patient experienced a mild increase in AEC from $160/\text{mm}^3$ to $>300/\text{mm}^3$ approximately 1 month after initiating pembrolizumab monotherapy and had a second increase to $700/\text{mm}^3$ roughly 2 weeks after receiving the first dose of ipilimumab plus nivolumab. The peak AEC of $3600/\text{mm}^3$ occurred 2 months after dual checkpoint inhibitor treatment (Fig. 1). Two cases of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to immune checkpoint inhibition have also been reported [13, 14]. Although our patient did present with rash and systemic symptoms including cough and gastrointestinal complaints, DRESS syndrome seemed less likely in the absence of fever, lymphadenopathy, extensive rash covering the face and greater than 50% of the body surface area, and typical involvement of the kidney or liver. He had a mild transaminitis attributed to radiation therapy that resolved prior to initiation of steroids.

Prior reports additionally suggest that baseline elevation in eosinophil count [15, 16] or increase during treatment with checkpoint inhibition [17] may serve as predictive biomarkers of improved response and survival outcomes as well as increased risk of immune-related adverse events in melanoma patients. For example, in a retrospective analysis of 616 patients with advanced melanoma treated with pembrolizumab, baseline relative eosinophil count (REC) $\geq 1.5\%$ was an independent prognosticator of improved overall survival (median OS 19.6 months vs 5.8 months in patients with REC ≥ 1.5 and $< 1.5\%$ respectively) [15]. Similarly, improved response rates and long-term disease control were observed in metastatic melanoma patients who experienced an increase in AEC of $>100/\text{mm}^3$ or had an AEC $>400/\text{mm}^3$ at 12 weeks after initiating anti-PD-1 therapy [17]. 22 of 73 patients (30%) with advanced melanoma treated

with ipilimumab at a single institution developed hyper-eosinophilia (defined as an AEC $> 400/\text{mm}^3$) during the course of their treatment [18]. An increase in AEC of greater than $100/\text{mm}^3$ between the first and second infusions was associated with longer survival (median OS 11.3 months versus 6.8 months, $p = 0.012$), and 73% of these patients had immune-related adverse events primarily involving the gastrointestinal tract. None of these adverse events were thought to be directly related to the hypereosinophilia, though biopsies of the affected organ were not obtained in all cases. Our patient had initial radiographic progression followed by several months of stable disease, but whether disease control was secondary to delayed immunotherapy response or receipt of other regimens such as trametinib and chemotherapy is unclear. Interestingly, a recent case report of hypereosinophilia in a non-small cell lung cancer patient who had lethal, hyperprogressive disease after a single dose of nivolumab highlights a more complex, context-specific role for eosinophils in which the immune modulatory effects of eosinophils may depend on which cytokines are present in the immediate surroundings [19]. TNF- α and IFN- γ appear to enhance eosinophilic production of pro-inflammatory Th1-type chemokines such as CXCL9 and CXCL10 whereas TNF- α and IL-4 stimulate eosinophilic production of Th2-type chemokines, which sustain a more immunosuppressive tumor microenvironment.

The immunological role of eosinophils is not fully understood, but they are implicated in various immune processes including host immune response to helminthic infections, pathogenesis of atopic conditions, and tumor surveillance. Eosinophils may promote antitumor immunity by recruiting CD8 $^+$ T cells to the tumor microenvironment via secretion of chemoattractants (CCL5, CXCL9, and CXCL10) and normalization of tumor vasculature, thereby allowing for increased effector T cell infiltration [20]. Moreover, eosinophils may polarize tumor-associated macrophages toward an M1 phenotype [20] and mediate direct tumor cell lysis via the release of granule-associated cytotoxic proteins including major basic protein, eosinophil peroxidase, and eosinophil-derived neurotoxin. Indeed, IL-5 transgenic mice expressing high endogenous levels of eosinophils displayed resistance to the development of methylcholanthrene (MCA)-induced fibrosarcomas [21]. In the case we present, it remains unclear whether there was any correlation between the eosinophilia and period of stable disease given the patient received multiple subsequent lines of therapy.

Conclusion

We present a case of dual checkpoint inhibitor-associated hypereosinophilia and eosinophilic enteritis in a patient with advanced cutaneous melanoma. Rapid resolution of

peripheral eosinophilia and associated symptoms was achieved with steroids alone. To our knowledge, this is the first case report of a direct clinical manifestation of hypereosinophilia due to immunotherapy.

Acknowledgements

N/A

Authors' contributions

JY, SML, YMS, and RDC contributed to the writing of the manuscript. SL contributed pathology images. All authors read and approved the final manuscript.

Funding

N/A

Availability of data and materials

N/A

Ethics approval and consent to participate

Columbia University requirements (http://www.cumc.columbia.edu/dept/irb/policies/docs/Case_Report_Policy.doc):

Case report on a single patient: A case report describing the treatment of a single patient does not meet the federal definition of human subjects research on the basis that the information in the case report is not generalizable knowledge. Therefore, clinicians at the University are not required to obtain IRB approval for case reports of a single patient. Investigators who are asked by a journal or other entity to provide documentation from the IRB that such a case report was either approved by the IRB or did not require review by the IRB may present the Columbia University IRB/Privacy Board Policy on Case Reports as evidence that the case report does not require IRB approval.

Consent for publication

Consent was obtained.

Competing interests

RDC serves as a consultant to Array, BMS, Castle Biosciences, Compugen, Foundation Medicine, Immunocore, I-Mab, Incyte, Merck, Roche/Genentech, PureTech Health, Sanofi Genzyme, and Sorrento Therapeutics. RC is also on the advisory board for Aura Biosciences, Chimeron, and Rgenix and receives research funding (to Columbia University) from Amgen, Astellis, AstraZeneca, Bayer, Bellicum, BMS, Corvus, Eli Lilly, Immunocore, Incyte, MacroGenics, Merck, Mirati, Novartis, Pfizer, Plexikon, and Roche/Genentech. YMS receives research and travel funding from Amgen. JY and SML declare that they have no competing interests.

Author details

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ²Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA. ³Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.

Received: 26 June 2019 Accepted: 16 September 2019

Published online: 15 November 2019

References

1. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). *J Allergy Clin Immunol*. 2004;113:11–28 quiz 9.
2. Lwin T, Melton SD, Genta RM. Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. *Mod Pathol*. 2011;24:556–63.
3. Pineton de Chambrun G, Dufour G, Tassy B, et al. Diagnosis, Natural History and Treatment of Eosinophilic Enteritis: a Review. *Curr Gastroenterol Rep*. 2018;20:37.
4. Khan S, Orenstein SR. Eosinophilic gastroenteritis. *Gastroenterol Clin N Am*. 2008;37:333–48 v.
5. Khan S. Eosinophilic gastroenteritis. *Best Pract Res Clin Gastroenterol*. 2005;19:177–98.

6. Caldwell JM, Collins MH, Stucke EM, et al. Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome. *J Allergy Clin Immunol*. 2014; 134:1114–24.
7. Zhang M, Li Y. Eosinophilic gastroenteritis: a state-of-the-art review. *J Gastroenterol Hepatol*. 2017;32:64–72.
8. Tsuyuki S, Tsuyuki J, Einsle K, Kopf M, Coyle AJ. Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. *J Exp Med*. 1997;185:1671–9.
9. Macdonald D, Gordon AA, Kajitani H, Enokihara H, Barrett AJ. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. *Br J Haematol*. 1990;76:168–73.
10. van Haelst PC, Kovach JS, Kita H, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. *Blood*. 1991;78:1538–44.
11. Sosman JA, Bartemes K, Offord KP, et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 1995;1:805–12.
12. Bernard-Tessier A, Jeanville P, Champiat S, et al. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. *Eur J Cancer*. 2017;81:135–7.
13. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. *PLoS One*. 2013;8:e53745.
14. Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. *Melanoma Res*. 2017;27:271–3.
15. Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with Pembrolizumab. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2016;22:5487–96.
16. Rosner S, Kwong E, Shoushtari AN, et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. *Cancer medicine*. 2018;7:690–7.
17. Gaba L, Victoria I, Pineda E. Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma. *J Clin Oncol* 2015;33, no. 15_suppl abstr 9069.
18. Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2013;24:1697–703.
19. Occhipinti M, Falcone R, Onesti CE, Marchetti P. Hyperprogressive disease and early Hypereosinophilia after anti-PD-1 treatment: a case report. *Drug safety - case reports*. 2018;5:12.
20. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. *Nat Immunol*. 2015;16:609–17.
21. Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. *J Immunol*. 2007;178:4222–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions